ADVR news, edit: actually not sure if its for ADVR, saw it on BOBZ under ADVR news and copied it over, I have no position just thought it looked interesting,
COMTEX) B: AIDS Treatment Activists Call for Fast Track Development
B: AIDS Treatment Activists Call for Fast Track Development of Reticulose
NEW YORK, Jul 26, 2000 /PRNewswire via COMTEX/ -- With the close of the 13th
International AIDS Conference, a coalition of leading AIDS Treatment activists
are demanding better access to Reticulose, a lipoprotein-nucleic acid complex
manufactured by Advanced Viral Research that has shown promise in the treatment
of many of the symptoms of HIV disease. Reticulose is presently available
through a compassionate use program approved by the FDA, but many activists are
claiming this is not enough.
"Many people presently receiving Reticulose through the compassionate access
program are doing better but there are hundreds of thousands of people living
with AIDS who need access to this promising therapy but can't receive it," said
David Miller, Director of Brooklyn Medical Arts AIDS CARE Center and a member of
ACT UP Brooklyn. "We are urging Advanced Viral Research to peruse federal
clinical research and to apply for fast track designation at the FDA to
accelerate access for the thousands that are intolerant to the side effects of
antiviral therapy."
Jeannie Gibbs, a veteran AIDS treatment activist now working with the
International HIV IBT Working Group is petitioning FDA officials and legislators
to move aggressively to ensure access to Reticulose. "I'm confident we're going
to secure the necessary support to encourage the development of Reticulose in
the next few weeks."
Advanced Viral Research is presently pursuing mature discussions with leading
clinical research organizations including Anderson Clinical Research Institute
who will be retained to execute trials in HIV patients during the next two to
three months.
Sources close to the company revealed that dramatic in vitro results of a study
analyzing the potential of Reticulose for the treatment of HIV will be submitted
for presentation during the 38th annual meeting of the Infectious Disease
Society of America taking place September 7-10, 2000 in New Orleans, LA.
SOURCE Brooklyn Medical Arts AIDS CARE Center
CONTACT: David Miller, 718-222-4600 or Jeannie Gibbs, both of Brooklyn
Medial Arts AIDS CARE Center
www.prnewswire.com
(C) 2000 PR Newswire. All rights reserved.
-0-
KEYWORD: New York
INDUSTRY KEYWORD: MTC
HEA
*** end of story *** |
